NCT02099474View on ClinicalTrials.gov

Evaluation of Raltegravir During the Third Trimester of Pregnancy

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

January 31, 2017

Study Completion Date

April 30, 2017

Conditions
HIV-1 InfectionPREGNANCY
Interventions
OTHER

Study of pharmacokinetic properties of raltegravir during the 3rd trimester of pregnancy

Introduction of a catheter for performing 5 blood samples in pregnant women infected by HIV-1, before the raltegravir intake, 0.5, 3, 8 and 12 hours after the intake at each of two visits (between 30 and 37 weeks of amenorrhea, and 4 to 6 weeks after delivery)

Trial Locations (1)

75004

CHU Hôtel Dieu, Paris

All Listed Sponsors
lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT02099474 - Evaluation of Raltegravir During the Third Trimester of Pregnancy | Biotech Hunter | Biotech Hunter